Restasis, expiring in its patent on the 17th, has shaken up the xerophthalmia market
Restasis(cyclosporine, Allergan Korea), which is well known as the first xerophthalmia treatment in the world, has shaken up the market as it will be expired in its patent on the 17th of this month.
Domestic companies, waiting for the expiration after acquiring generic approvals in advance, seem...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
